Hikal Ltd

- There is no specific mention of any current or immediate new fundraising through debt or equity in the call. - The company mentioned having a debt of Rs. 759 crores in Q1 FY25, reduced from Rs. 804 crores last quarter (a Rs. 45 crore reduction). - They plan to optimize CAPEX and improve debt-equity ratios starting next year, with a focus on continuous debt reduction. - Interest costs have increased due to capitalization of assets; these costs are expected to be absorbed over time as production ramps up. - CAPEX for the current year is guided to be around Rs. 120 to Rs. 140 crores, mainly for debottlenecking and maintenance, with no major significant CAPEX planned. - No explicit plans for raising funds via equity or debt were disclosed during the call.

- Current CAPEX guidance for FY25 is approximately Rs. 120 to Rs. 140 crores, primarily focused on debottlenecking and maintenance, with no major significant new CAPEX planned currently. - Recent CAPEX of Rs. 600 to Rs. 800 crores has been done over the last three years, achieving 1.3x to 1.5x asset turnover. - Capitalization of new assets in the last 12 months has increased depreciation and interest costs, expected to be absorbed as production and sales ramp up. - Future CAPEX is planned for expansion in Crop Protection, Animal Health, and Pharma divisions, with validation activities ongoing, and regulatory filings expected to significantly contribute to growth. - No specific large-scale strategic investments announced, but focus remains on capacity expansion, cost efficiencies, and operational optimization to support 10-15% growth from FY26 onwards.

- Hikal Limited expects 10%-15% CAGR growth over the next 2-3 years starting next fiscal year, driven by ramp-up in new molecules and normalization in crop protection demand (Page 13). - Pharma business anticipates good volume growth due to capacity expansions and robust product pipeline, with 2-3 new product launches annually (Page 5). - Crop protection business faces short-term challenges but expects market improvement by Q3/Q4 FY25, supporting mid to long-term growth (Pages 4, 7). - CDMO segment is seeing increased customer inquiries and opportunities, with projects expected to reach peak potential within 2 years (Pages 9, 10). - Animal health business is in validation phase, expecting revenues to start accruing around 14-16 months post-validation, indicating growth potential over next 5 years (Page 10). - Overall, the company aims to double revenue over 3-4 years from FY23 base of Rs. 2000 crores through diversification and new business streams (Page 11).

- Hikal Limited expects 10%-15% revenue CAGR over the next 2-3 years, starting next fiscal year, driven by recovery in crop protection and growth in pharma and animal health divisions. - EBITDA margins expected to reach historical levels of 18%-20% post FY26, with peak margin reflection anticipated about 3-5 years from now as new molecules scale up commercially (likely by FY29 or FY30). - Growth in pharma CDMO and niche specialty products will drive higher material gross margins, potentially north of 60%, improving blended margins from the current ~45%. - Operating leverage is expected with capacity debottlenecking and regulatory approvals, leading to better profitability through FY25 and beyond. - Interest costs currently higher due to asset capitalization but expected to reduce and improve net profits as production ramps up. - Focus remains on profitability and margin quality over aggressive growth; management is cautiously optimistic about sustainable and profitable expansion.

- The transcript does not provide explicit details about the current or expected order book or pending orders in quantitative terms. - However, it mentions a "growing number of inquiries and conversions to form business" in the CDMO segment, indicating a strong interest and pipeline. - The Crop Protection business is actively engaged in several projects with existing and new innovator customers, many in advanced stages of discussion. - The Animal Health segment is in the validation phase for several molecules with discussions ongoing for new customers, showing positive signs. - Overall, the company shows a robust product development pipeline with 8-9 products in progress and 2-3 new product launches expected annually. - Despite current industry challenges, there is confidence in improved market demand and expansion in new geographies, suggesting a healthy future order pipeline.